Effect of Plinabulin Plus Docetaxel vs Docetaxel Plus Placebo on Overall Survival of Patients With NSCLC After Disease Progression on Platinum-Based Regimen
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Respiratory Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Plinabulin plus docetaxel versus docetaxel in patients with non-small-cell lung cancer after disease progression on platinum-based regimen (DUBLIN-3): a phase 3, international, multicentre, single-blind, parallel group, randomised controlled trial
Lancet Respir Med 2024 Sep 06;[EPub Ahead of Print], B Han, T Feinstein, Y Shi, G Chen, Y Yao, C Hu, J Shi, J Feng, H Wu, Y Cheng, QS Guo, Z Jie, F Ye, Y Zhang, Z Liu, W Mao, L Zhang, J Lu, J Zhao, L Bazhenova, J Ruiz, GH Kloecker, KR Sujith, IA Oliff, M Wong, B Liu, Y Wu, L Huang, Y SunFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.